ArticleBMC infectious diseases2026
Host MiRNA responses during different waves of SARS-CoV-2: diagnostic implications of miR-19a-3p, miR-374b-5p, miR-15b-5p, and miR-320a-5p expression.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiven the pivotal roles of miRNAs as regulators of gene expression, circulating miRNAs offer promising non-invasive diagnostic and therapeutic avenues. The evolving landscape of SARS-CoV-2 variants poses challenges for traditional disease detection and control.
methodsTo unveil the specific circulating miRNA profiles linked to COVID-19 and its correlation with severity levels, qPCR was conducted on five potential miRNAs in plasma samples obtained from 112 COVID-19 patients (comprising 58 severe, 50 moderate, and four mild cases) upon hospital admission during two waves (Beta and Delta variants) of the pandemic, alongside samples from 112 healthy controls. Moreover, correlations between miRNA expression and various clinical laboratory parameters were investigated.
resultsTwo miRNAs, including miR-19a-3p and miR-374b-5p, were upregulated, and two were downregulated (miR-15b-5p and miR-320a-5p), while the miR-423-5p expression was not changed in COVID-19 patients. ROC curve analysis demonstrated that miR-15b-5p and miR-320a-5p showed the highest specificity and sensitivity. In addition, significant correlations were found between miRNA expression and various laboratory parameters, suggesting that these miRNAs may serve as potential biomarkers for disease severity and progression. Further analysis during different COVID-19 waves and severity levels revealed consistent miRNA expression patterns among the two waves of infection, and most importantly, significant changes in expression among the mild/moderate versus severe infected patients, underscoring their diagnostic value upon different virus strain infections.
conclusionWhile miRNAs do not replace RT-PCR for viral detection, they offer valuable diagnostic insights into host response and disease dynamics, and may enhance early screening, risk stratification, and monitoring in clinical settings. This study highlights the role of miRNAs as non-invasive biomarkers for the diagnosis and monitoring of COVID-19. In conclusion, the SARS-CoV-2 virus is constantly evolving and mutating. The data presented here explores the distinct role of circulating miRNAs within individuals affected by different variants of COVID-19, unveiling their promise as non-invasive diagnostic markers. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.